What is Jaguar Health Financial Strength?
Jaguar Health has the Financial Strength Rank of 1. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.
Warning Sign:
Jaguar Health Inc displays poor financial strength. Usually, this is caused by too much debt for the company.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Jaguar Health did not have earnings to cover the interest expense.
Jaguar Health's debt to revenue ratio for the quarter that ended in Dec. 2023 was 4.03.
As of today, Jaguar Health's Altman Z-Score is -9.65.
Competitive Comparison of Jaguar Health's Financial Strength
For the Biotechnology subindustry, Jaguar Health's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jaguar Health's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jaguar Health's Financial Strength distribution charts can be found below:
* The bar in red indicates where Jaguar Health's Financial Strength falls into.
Jaguar Health Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Jaguar Health's Interest Expense for the
months ended in Dec. 2023 was $-0.25 Mil. Its Operating Income for the
months ended in Dec. 2023 was $-7.19 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $31.88 Mil.
Jaguar Health's Interest Coverage for the quarter that ended in Dec. 2023 is
| Jaguar Health did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Jaguar Health's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Jaguar Health has a Z-score of -9.65, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of -9.65 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jaguar Health (Jaguar Health) Business Description
Traded in Other Exchanges
Address
200 Pine Street, Suite 400, San Francisco, CA, USA, 94104
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments-human health and animal health. The company generates the majority of its revenue from the Human Health segment.
Executives
| Anula Jayasuriya |
director |
5150 EL CAMINO REAL, SUITE #A-32, LOS ALTOS CA 94022 |
| Pravin R Chaturvedi |
officer: Chief Scientific Officer |
C/O JAGUAR HEALTH INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO CA 94104 |
| Lisa A Conte |
director, officer: CEO & President |
213 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
| Carol R. Lizak |
officer: Chief Accounting Officer |
201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105 |
| James J Bochnowski |
director |
C/O DELPHI VENTURES, 160 BOVET RD, SUITE 408, SAN MATEO CA 94402 |
| Jonathan S. Wolin |
officer: Chief of Staff, CCO & GC |
201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105 |
| Jonathan B. Siegel |
director |
C/O KINGDON CAPITAL MANAGEMENT, L.L.C., 152 WEST 57TH STREET, 50TH FLOOR, NEW YORK NY 10019 |
| Bryan Ezralow 1994 Trust Dated December 22, 1994 |
10 percent owner |
23622 CALABASAS ROAD, SUITE 200, CALABASAS CA 91302 |
| Bryan Ezralow |
10 percent owner |
THE EZRALOW CO, LLC, 23622 CALABASAS ROAD, SUITE 200, CALABASAS CA 91302-1549 |
| Nantucket Investments Ltd |
10 percent owner |
PO BOX 282, REGENCY COURT, GLATEGNY ESPLANADE, ST PETER PORT Y7 GY1 3RH |
| Jonathan M Glaser |
10 percent owner |
11601 WILSHIRE BLVD., SUITE 2180, LOS ANGELES CA 90025 |
| Murray David Macnaughtan |
director |
C/O JAGUAR HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105 |
| Greg J Divis |
director |
10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15 |
| Jeffery C. Johnson |
director |
C/O SAGARD CAPITAL PARTNERS, L.P., 280 PARK AVENUE, 3F WEST, STAMFORD CT 06901 |
| Sagard Capital Partners, L.p. |
10 percent owner |
280 PARK AVENUE, 3RD FLOOR WEST, NEW YORK NY 10017 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
JAGX has been successfully added to your